NewsPublicHealth.com : Public Health News

VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth patents to be granted in a series of patent applications VIVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications.

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces that the United States Patent and Trademark Office recently granted the company Patent Number 7,660,448. This patent covers future iterations of iCAD’s SecondLook® Digital Computer-Aided Detection (CAD) solution with potential application to the company’s other image analysis solutions.

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson’s Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.

Kinetic Concepts, Inc. today announced that a United States District Court jury has found that a negative pressure wound therapy (NPWT) product marketed and sold by Smith & Nephew plc (NYSE: SNN) infringes two patents owned by Wake Forest University Health Sciences, which are exclusively licensed to KCI.

Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson’s generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.

The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc., notes the decision returned today by a jury in the patent litigation brought by Kinetic Concepts Inc. before the U.S. District Court for the Western District of Texas. In that case, the jury found U.S. Patent Nos. 5,645,081 and 7,216,651 to be infringed by Smith & Nephew’s RENASYS-F (Foam) Dressing Kit, which delivers Negative Pressure Wound Therapy to patients in need.

Precision BioSciences, Inc., today announced that the Opposition Division of the European Patent Office has issued a written decision confirming its November 18, 2009 revocation of the previously granted claims of Cellectis’ European Patent No. 1 485 475.

Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics’ ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.

Intellipharmaceutics International Inc. today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride).

Amgen announced today that the United States (U.S.) District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen’s patents on recombinant erythropoietin (EPO), thus bringing the five-year patent infringement dispute to an end.

Retractable Technologies, Inc. (“Retractable”) (AMEX: RVP), a leading maker of safety needle devices, announced today that a Tyler, Texas jury returned a verdict on Friday, December 18th in the litigation of Retractable Technologies, Inc. v. OMI (Occupational & Medical Innovations Limited, an Australian public company,) in favor of Retractable on all claims presented to the jury.

OSI Pharmaceuticals, Inc. today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065, replacing Tarceva’s® (erlotinib) composition of matter patent (formerly No.5,747,498). The Company had applied for the reissue patent in February 2008, and on September 17, 2009 the Company had announced that the PTO had issued a “Notice of Allowance” accepting the Company’s application to correct certain errors relating to the claiming of compounds, other than Tarceva, which had fallen outside of the scope of the main claim of the patent.

EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that the U.S. Patent and Trademark Office has issued a key patent covering its SerosaFuse fastener and “over the wire” delivery system.

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received notification from the European Patent Office (EPO) that Advaxis patent application 98957980.0 titled “Bacterial Vaccines Comprising Auxotrophic, Attenuated Strains of Listeria Expressing Heterologous Antigens,” has been granted and will be issued as patent #1032417

Cipher Pharmaceuticals Inc. today announced a final judgment (the “Cipher Judgment”) has been entered in favour of Cipher in relation to pending patent litigation with Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. (together “Purdue”) in the United States District Court for the Eastern District of Virginia (the “Court”).

Microfluidic Systems (MFSI), a privately-held company, announced today that it has been awarded a series of patents covering both the components and integrated systems that perform fully automated sample collection through identification of air-borne pathogens such as bacteria, viruses, and toxins.

CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled “Sulfoalkyl Ether Cyclodextrin Compositions.” This patent, along with other previously issued technology patents, will provide broad protection for CyDex’s Captisol® technology until 2029.

Response Biomedical Corporation announced today that the Company has received a Notice of Allowance from the European Patent Office for the patent entitled “Sensitive Immunochromatographic Assay”, referred to as the “Fong Patent”.

Trim Holding Group (”the Company”) announced that on December 31, 2009 the Company purchased patent rights under a patent agreement signed with Allkey Ltd. In consideration of the patent rights, the Company issued 3,750,000 preferred shares with a par value of $7.00/share.

CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled “Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof.” This patent, along with other previously issued technology patents, will provide broader protection for CyDex’s Captisol® technology until 2028.

A depression drug created and patented by a team of University of South Florida researchers is at the center of major deal between global pharmaceutical company AstraZeneca PLC and Targacept, Inc., earning the university its potentially most lucrative patent royalties to date.

AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product.

American Diversified Holdings Corporation has announced, as part of its previously disclosed strategy to concentrate in developing innovative technologies in the life sciences sector, specifically targeting the fast growing stem cell arena, that the Company is actively seeking to acquire stem cell patents for the express purpose of developing these patents for commercial purposes.

Neurology researchers have shown that feeding amino acids to brain-injured animals restores their cognitive abilities and may set the stage for the first effective treatment for cognitive impairments suffered by people with traumatic brain injuries.

LinkMed’s subsidiary AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product. The European countries are highly prioritized markets for AbSorber and the patent approval is an important milestone in Absorbers intellectual property strategy.

Palatin Technologies, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled “Cyclic Natriuretic Peptide Constructs.” The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin’s lead heart failure drug candidate.

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced the filing of a new United States patent application entitled “POU5-F1 Expression in Human Mesenchymal Stem Cells” and the development of new technology related to generation of human induced pluripotent stem cells (iPS).

Cephalon, Inc. today announced that it has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent Nos. 7,132,570 (the “‘570 Patent”), 7,297,346 (the “‘346 Patent”) and RE37,516 (the “‘516 Patent”) for the Cephalon product NUVIGIL® (armodafinil) Tablets [C-IV].

Non-Invasive Monitoring Systems, Inc. announced that the Canadian Patent Office issued Patent number 2,534,302 to NIMS on October 20, 2009. The patent, entitled “Reciprocating Movement Platform for the External Addition of Pulses to the Fluid Channels of a Subject”, relates to the comprehensively researched technology underlying NIMS’ Exer-Rest acceleration therapeutic platform.

VirtualScopics, Inc., a leading provider of quantitative imaging for clinical trials, announced today that its patent titled “System and Method for 4D Reconstruction and Visualization” recently received issuance in Japan.

Smokefree Innotec, Inc. announced today that its Swiss patent and trademark attorneys Spierenburg & Partners AG have started nationalizing and regionalizing the PCT patent application for SFIO’s Real Smokefree product.

Northwest Biotherapeutics, Inc. (”NWBT” or the “Company”) announced today that the US Patent and Trademark Office has allowed its patent application on a system for automation of the initial stages of the manufacture of the Company’s DCVax® therapeutic cancer vaccines.

ACUO TECHNOLOGIES, developers of high-performance medical image management software, data migration tools and services, is pleased to announce that the United States Patent and Trademark Office has approved a patent application for an “Asset Communication Format within a Computer Network.”

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

Applied Spine Technologies, Inc., a medical device company focused on motion preservation of the lumbar spine, has been awarded a new patent titled “Mounting mechanisms for pedicle screws and related assemblies”.

Depomed, Inc. today announced that it has filed a lawsuit in the United States District Court for the Northern District of California against Lupin Limited and its wholly-owned subsidiary, Lupin Pharmaceuticals, Inc., for infringement of the patents listed in the Orange Book for GLUMETZA® (metformin hydrochloride extended release tablets).

Titan Pharmaceuticals, Inc today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Titan’s United States patent application directed to the use of Probuphine for the treatment of opiate addiction.

4SC AG, a drug discovery and development company, today announced that the European Patent Office has granted patent EP1392642, which covers its lead auto-immune compound 4SC-101.

Kemin Foods, L.C. (”Kemin”) and OmniActive Health Technologies, Inc. and OmniActive Health Technologies, Ltd. (”OmniActive”) have reached an amicable settlement of their dispute.

DJO Incorporated, a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that its Chattanooga division was issued U.S. Patent No. 7597656 for Chattanooga’s new Moveo XP Rehabilitation Platform. The Moveo XP is the first product of its kind, allowing patients who are incapable of supporting full body weight to participate in graded weight-bearing activity at an earlier stage in their physical rehabilitation.

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition.

NOD Pharmaceuticals Inc. announced the US Patent & Trademark Office (PTO) has allowed the patent application for its nano-particle oral delivery or NOD technology.

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has filed a motion to stay, or discontinue all proceedings in, the patent infringement lawsuit brought against it in October 2009 by Cook, Inc.

Unilife Medical Solutions Limited today announced the filing of patent applications in the United States (”US”) for a new ready-to-fill syringe product to be marketed as the Unifill™ Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company’s ability to penetrate the pharmaceutical market for prefilled syringes.

Cardio Vascular Medical Device Corp., a leading developer of advanced cardiovascular surgery technology, today announced that the company’s Board of Directors has decided to initiate patent applications in Europe, Canada and the Far East for its proprietary next-generation “steerable guidewire” applicable for all angioplasty (PCTA) procedures.

Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled “Microfluidic Valve Mechanism”. This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge.

RAE Systems Inc., a leader in delivering innovative sensor solutions to serve energy, hazardous material management, industrial safety, government safety and environmental markets worldwide, was granted U.S. Patent 7,592,603 B2 for a gamma radiation detector that can perform both rate and dose measurements simultaneously.

Expression Pathology, a leader in tissue proteomic analysis, today announced Mayo Clinic has licensed non-exclusive rights to Expression Pathology’s Liquid Tissue® patent for use in diagnosis of systemic amyloidosis in formalin-fixed tissue.

Entest BioMedical Inc. (OTC Bulletin Board: ENTB) announced today the filing of a third patent application relating to the area of chronic obstructive pulmonary disease (COPD), a condition that affects more than 5 million patients in the United States, resulting in more than 120,000 deaths per year. The application covers an implantable medical device useful in re-directing the immune system to stop tissue inflammation.